The global chronic refractory cough treatment market is expected to reach a valuation of USD 9.2 billion in 2023 and is projected to reach USD 17.1 billion by 2033, trailing a CAGR of 6.39%.
The growing prevalence of refractory chronic cough globally drives the refractory chronic cough therapeutics market. Increased global healthcare spending and disease awareness would increase the market's size, allowing pharmaceutical companies to expand their market share. The medicines in development are centered on cutting-edge methods to treat or ameliorate the illness state.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 9.2 billion |
| Anticipated Forecast Value (2033) | USD 17.1 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 6.39% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The chronic refractory cough treatment market was worth USD 7 billion in 2018 while growing at a CAGR of 5.62%. In order to relieve patients from cough hypersensitivity, healthcare companies are investing in opiates and GABA (gamma-aminobutyric acid)-related compounds. Opiates serve as effective cough suppressants and possess efficacious antitussive properties to treat chronic intractable cough. Likewise, companies are increasing their production capabilities of tramadol, an opioid medication that is similar to the molecular formula of codeine drugs.
Since chronic cough causes increased body pain, companies in the Chronic refractory cough treatment market are increasing the availability of gabapentin and pregabalin, which are GABA-related compounds, and act as neuromodulators for the treatment of neuropathic pain and epilepsy. It has been found in placebo-controlled trials that; gabapentin is well-tolerated for the treatment of refractory chronic cough. Thus, leading to market expansion.
Considering these factors, the market for Chronic refractory cough treatment is projected to reach USD 17.1 billion by end of the forecast period, while exhibiting a CAGR of 6.39%.
Launch of pipeline therapies augmenting the market expansion
The launch of pipeline therapies in late and mid-stage developments, including Orvepitant Maleate, BLU-5937, Gefapixant, BAY1817080, and S-600918, is anticipated to expand the growth quadrant of the Chronic Refractory Cough market size in the coming years. Gefapixant (Merck) is currently in the Phase III stage of development, followed by Orvepitant Maleate (Nerre Therapeutics) which will support market growth.
Also, the use of various off-label therapies and over-the-counter drugs like Neuro-modulating agents (Opioids, Baclofen, Gabapentin, Pregabalin, and Amitriptyline), Proton Pump inhibitors, Inhaled corticosteroids (ICS), and others along with non-pharmacological treatments like speech therapy will fuel product demand. Orvepitant Maleate has demonstrated no safety concerns in the treated population with excellent tolerability. If approved, the drug has the potential to capture a major market share. Thus, leading to market expansion.
Lack of approved therapies to restrain the growth
A severe dearth of approved therapies in the chronic refractory cough treatment market may restrain its success trajectory. There is a lack of availability of specific biomarkers that can help in the accurate and timely diagnosis of Chronic Refractory Cough. These factors will hamper market expansion.
North America leading the market with a significant market share
The North American chronic refractory cough treatment market is projected to reach USD 6.84 billion by 2033 from USD 3.9 billion in 2023. It is estimated to grow with a CAGR of 5.77% during the forecast period. This region is expected to dominate the market with a 40% market share, owing to the presence of major market players.
The USA leads the market in this region with approximately 71% market share. Several collaborative efforts were undertaken by major companies to enhance their Research and Development capabilities and ensure high medical standards are expected to impel the demand across this region. Moreover, the majority share can also be attributed to the high disease burden in this region. Rising cases of cough and the rising pediatric population are the key factors that are fuelling the market in this region.
South Asian market to witness the fastest growth
South Asia region is expected to witness the fastest growth of 6.2% over the forecast period. The market in this region is estimated to be worth USD 4.78 billion, accounting for 28% market share by end of the forecast period.
Strategic partnerships between pharmaceutical companies and government organizations are on a rise in the region, particularly to develop generic drugs and spread awareness amongst healthcare professionals. Growing awareness levels and the rising focus of healthcare providers on the eradication of coughing ailments are expected to boost growth within this region.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Retail Pharmacies are dominating the market and driving growth
The retail pharmacy segment is expected to dominate the market with a 55% market share. Growth is attributable to the easy availability and accessibility of these pharmacies. For instance, MedPlus has around 1650 outlets out of which 1,350 are self-owned and the rest are taken as a franchisee. Retailers provide discounts on bulk purchases, offer quick delivery, and always have sufficient product stock, owing to which consumers opt for these distribution channels, thus, driving the segment’s growth.
Online Pharmacies to experience Maximum Sales of Chronic Refractory Cough Treatment Drugs
Online pharmacies are estimated to be the fastest-growing segment with a CAGR of 8% during the forecast period. The convenience of delivering medicines to the doorstep is the major advantage of online pharmacies.
The discounted price that online pharmacies offer is also a factor that drives the growth of the Chronic refractory cough treatment market. As per an estimate, there are between 30,000 and 50,000 online pharmacies operating in the United States alone, making online pharmacies a leading segment in this region.
Antibiotics to take the lead and drive market growth
This segment is projected to achieve a 45.7% market share by end of the forecast period. The growing usage of antibiotic drugs for the treatment of chronic refractory cough and ongoing research on the development of effective antibiotic therapies are leading to the growth of the antibiotic drug class segment in the global chronic refractory cough treatment market.
The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are: Bayer AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Mylan N.V., GlaxoSmithKline, Hikma Pharmaceuticals Plc, AstraZeneca, Bausch Health, Novartis AG, Cipla Inc, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd, Alitair Pharmaceuticals, NeRRe Therapeutics, Amneal Pharmaceuticals, Inc
Some recent developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 9.2 billion |
| Market Value in 2033 | USD 17.1 billion |
| Growth Rate | CAGR of 6.39% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, India, China, Japan, Malaysia, Singapore, Thailand, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Bayer AG; Sun Pharmaceutical Industries Ltd; Aurobindo Pharma Ltd; Mylan N.V.; GSK Plc.; Hikma Pharmaceuticals Plc; AstraZeneca Plc.; Bausch Health; Novartis AG; Cipla Inc.; Glenmark Pharmaceuticals Ltd.; Teva Pharmaceutical Industries Ltd; Alitair Pharmaceuticals; NeRRe Therapeutics; Amneal Pharmaceuticals Inc. |
| Customization | Available Upon Request |
FMI projects the global Chronic Refractory Cough treatment market to expand at a 6.39 % value CAGR by 2033.
The global chronic refractory cough treatment market is expected to garner a market value of USD 17.1 billion by 2033.
FMI has projected North America to be one of the most profitable regions for the chronic refractory cough treatment market.
South Asia region is expected to grow fastest during the forecast period, expanding at a 6.2% CAGR
The market in 2023 is valued at USD 9.2 billion.
The market is anticipated to experience a 6.39% CAGR from 2023 to 2033.
From 2018 to 2022, the market expanded at a 5.62% CAGR.
By 2033, the market is estimated to reach USD 17.1 billion.
South Asia is likely to expand at a CAGR of 6.2% over the forecast period.
| Expected Base Year Value (2024) | USD 42,618.7 million |
|---|---|
| Anticipated Forecast Value (2034) | USD 59,539.6 million |
| Estimated CAGR (2024 to 2034) | 3.40% CAGR |
| Market Value (2022) | USD 1,996.1 Million |
|---|---|
| Market Anticipated Forecast Value (2032) | USD 3,495.3 Million |
| Market Projected CAGR (2022 to 2032) | 5.2% |
Explore Therapy Area Insights
View Reports
Chronic Refractory Cough Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
